Amy Belnap
Psychiatric/Mental Health, Child & Adolescent · Chubbuck, IDNPI 1699202044
Payments from drug & device makers
Across 1,078 payments — averaging $525.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$238K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$201K
- E.r. Squibb & Sons, L.L.C.$73K
- Axsome Therapeutics, Inc.$49K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$560
- plus $3K from 22 others
What the payments were for
- Consulting fees$53,5309%
- Speaking & faculty fees$433,85677%
- Travel & lodging$59,74611%
- Food & beverage$19,2983%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 255 | $237,707 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 347 | $201,182 |
| E.r. Squibb & Sons, L.L.C. | 87 | $73,353 |
| Axsome Therapeutics, Inc. | 77 | $48,821 |
| AbbVie(2 entities) | 120 | $1,860 |
| Teva Pharmaceuticals USA, Inc. | 38 | $560 |
| Otsuka America Pharmaceutical, Inc. | 26 | $485 |
| Johnson & Johnson | 16 | $435 |
| Alkermes, Inc. | 18 | $426 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $355 |
| Tris Pharma Inc | 6 | $290 |
| Supernus Pharmaceuticals, Inc. | 12 | $246 |
| Vanda Pharmaceuticals Inc. | 8 | $178 |
| Corium, LLC | 14 | $143 |
| Eisai Inc. | 5 | $111 |
| Ironshore Pharmaceuticals Inc. | 6 | $105 |
| Lundbeck LLC | 5 | $86 |
| Merck | 1 | $78 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Genentech USA, Inc. | 2 | $33 |
| Indivior Inc. | 1 | $18 |
| Braeburn Inc. | 1 | $18 |
| Biogen | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$233,719
- CAPLYTA$196,823
- COBENFY$69,857
- Auvelity$47,674
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
How this compares
Too few psychiatric/mental health, child & adolescent providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 65 | $552,833 |
| SpravatoEsketamine Hcl | 108 | $449,623 |
| VraylarCariprazine Hcl | 184 | $258,162 |
| CaplytaLumateperone Tosylate | 97 | $159,954 |
| Invega TrinzaPaliperidone Palmitate | 12 | $116,079 |
| AristadaAripiprazole Lauroxil | 27 | $92,718 |
| PerserisRisperidone | 32 | $87,186 |
| LybalviOlanzapine/Samidorphan Malate | 38 | $62,207 |
| FanaptIloperidone | 22 | $55,972 |
| VivitrolNaltrexone Microspheres | 30 | $48,918 |
| AuvelityDextromethorphan Hbr/Bupropion | 66 | $48,036 |
| TrintellixVortioxetine Hydrobromide | 69 | $36,615 |
| BelsomraSuvorexant | 78 | $33,914 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $25,459 |
| DayvigoLemborexant | 60 | $21,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Trinza | $435 | $565,702120 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $237,707 | $560,46776 claims |
| AbbVieVraylar | $1,860 | $258,162184 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $426 | $203,84395 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $201,182 | $159,95497 claims |
| Indivior Inc.Perseris | $18 | $87,18632 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $178 | $55,97222 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $355 | $49,663102 claims |
| Axsome Therapeutics, Inc.Auvelity | $48,821 | $48,03666 claims |
| MerckBelsomra | $78 | $33,91478 claims |
| Eisai Inc.Dayvigo | $111 | $21,12560 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $105 | $5,34211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, child & adolescent providers in Idahoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.